Annual EBITDA
-$374.15 M
-$67.33 M-21.94%
December 31, 2023
Summary
- As of February 7, 2025, RLAY annual EBITDA is -$374.15 million, with the most recent change of -$67.33 million (-21.94%) on December 31, 2023.
- During the last 3 years, RLAY annual EBITDA has fallen by -$321.91 million (-616.12%).
- RLAY annual EBITDA is now -683.81% below its all-time high of -$47.73 million, reached on December 31, 2018.
Performance
RLAY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$95.00 M
+$15.76 M+14.23%
September 1, 2024
Summary
- As of February 7, 2025, RLAY quarterly EBITDA is -$95.00 million, with the most recent change of +$15.76 million (+14.23%) on September 1, 2024.
- Over the past year, RLAY quarterly EBITDA has dropped by -$21.59 million (-29.41%).
- RLAY quarterly EBITDA is now -364.63% below its all-time high of $35.90 million, reached on December 31, 2020.
Performance
RLAY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$389.45 M
-$21.59 M-5.87%
September 1, 2024
Summary
- As of February 7, 2025, RLAY TTM EBITDA is -$389.45 million, with the most recent change of -$21.59 million (-5.87%) on September 1, 2024.
- Over the past year, RLAY TTM EBITDA has dropped by -$25.96 million (-7.14%).
- RLAY TTM EBITDA is now -2375.07% below its all-time high of -$15.73 million, reached on March 31, 2019.
Performance
RLAY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RLAY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | -29.4% | -7.1% |
| 3 y3 years | -616.1% | -63.9% | -221.0% |
| 5 y5 years | -683.8% | -346.6% | -379.6% |
RLAY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -67.7% | at low | -44.3% | +14.2% | -74.6% | at low |
| 5 y | 5-year | -616.1% | at low | -364.6% | +14.2% | -645.4% | at low |
| alltime | all time | -683.8% | at low | -364.6% | +14.2% | -2375.1% | at low |
Relay Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$95.00 M(-14.2%) | -$389.45 M(+5.9%) |
| Jun 2024 | - | -$110.76 M(+22.0%) | -$367.87 M(+1.1%) |
| Mar 2024 | - | -$90.80 M(-2.2%) | -$363.97 M(-2.7%) |
| Dec 2023 | -$374.15 M(+21.9%) | -$92.89 M(+26.5%) | -$374.15 M(+2.9%) |
| Sep 2023 | - | -$73.41 M(-31.3%) | -$363.49 M(-2.2%) |
| Jun 2023 | - | -$106.87 M(+5.8%) | -$371.68 M(+8.8%) |
| Mar 2023 | - | -$100.98 M(+22.8%) | -$341.46 M(+11.3%) |
| Dec 2022 | -$306.82 M(+37.5%) | -$82.23 M(+0.8%) | -$306.82 M(+5.6%) |
| Sep 2022 | - | -$81.60 M(+6.4%) | -$290.45 M(+8.9%) |
| Jun 2022 | - | -$76.66 M(+15.5%) | -$266.83 M(+7.6%) |
| Mar 2022 | - | -$66.34 M(+0.7%) | -$247.94 M(+11.1%) |
| Dec 2021 | -$223.08 M | -$65.85 M(+13.6%) | -$223.08 M(+83.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$57.98 M(+0.4%) | -$121.33 M(+22.5%) |
| Jun 2021 | - | -$57.77 M(+39.2%) | -$99.05 M(+45.4%) |
| Mar 2021 | - | -$41.49 M(-215.6%) | -$68.13 M(+30.4%) |
| Dec 2020 | -$52.25 M(-35.7%) | $35.90 M(-200.6%) | -$52.25 M(-53.8%) |
| Sep 2020 | - | -$35.69 M(+32.9%) | -$113.13 M(+14.6%) |
| Jun 2020 | - | -$26.85 M(+4.9%) | -$98.71 M(+8.4%) |
| Mar 2020 | - | -$25.60 M(+2.5%) | -$91.07 M(+12.1%) |
| Dec 2019 | -$81.20 M(+70.1%) | -$24.98 M(+17.4%) | -$81.20 M(+44.4%) |
| Sep 2019 | - | -$21.27 M(+10.7%) | -$56.22 M(+60.9%) |
| Jun 2019 | - | -$19.21 M(+22.1%) | -$34.95 M(+122.1%) |
| Mar 2019 | - | -$15.73 M | -$15.73 M |
| Dec 2018 | -$47.73 M | - | - |
FAQ
- What is Relay Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Relay Therapeutics?
- What is Relay Therapeutics annual EBITDA year-on-year change?
- What is Relay Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Relay Therapeutics?
- What is Relay Therapeutics quarterly EBITDA year-on-year change?
- What is Relay Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Relay Therapeutics?
- What is Relay Therapeutics TTM EBITDA year-on-year change?
What is Relay Therapeutics annual EBITDA?
The current annual EBITDA of RLAY is -$374.15 M
What is the all time high annual EBITDA for Relay Therapeutics?
Relay Therapeutics all-time high annual EBITDA is -$47.73 M
What is Relay Therapeutics annual EBITDA year-on-year change?
Over the past year, RLAY annual EBITDA has changed by -$67.33 M (-21.94%)
What is Relay Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RLAY is -$95.00 M
What is the all time high quarterly EBITDA for Relay Therapeutics?
Relay Therapeutics all-time high quarterly EBITDA is $35.90 M
What is Relay Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RLAY quarterly EBITDA has changed by -$21.59 M (-29.41%)
What is Relay Therapeutics TTM EBITDA?
The current TTM EBITDA of RLAY is -$389.45 M
What is the all time high TTM EBITDA for Relay Therapeutics?
Relay Therapeutics all-time high TTM EBITDA is -$15.73 M
What is Relay Therapeutics TTM EBITDA year-on-year change?
Over the past year, RLAY TTM EBITDA has changed by -$25.96 M (-7.14%)